Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
18 10 2019
Historique:
received: 07 11 2018
pubmed: 20 6 2019
medline: 30 5 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

Fistulas may arise as a relevant complication of Crohn's disease (CD). Despite their clinical significance and the substantial burden imposed on patients, limited data are available on the epidemiology of fistulizing CD in the United States. A systematic literature review was conducted to identify data published between 1970 and 2017 on the epidemiology of fistulas in patients with CD, with the aim to estimate the number of prevalent cases in the United States. Retrieved titles and abstracts were screened by 2 independent researchers for inclusion criteria (US population-based studies reporting data on the epidemiology of fistulizing CD). To validate the literature-based estimate, data from a US claims database (Truven Health MarketScan database) were analyzed. This database has broad geographic coverage, with health care data for >60 million patients during the period of the analysis. The literature search retrieved 7 articles for full-text review, and only 1 met the criteria for inclusion. This study described the cumulative incidence of fistulas in a CD population from Minnesota over 20 years. From the reported data, the estimated number of prevalent cases with fistulizing CD in the United States was ~76,600 in 2017 (~52,900 anal, ~7400 rectovaginal, ~2300 enterocutaneous, and ~14,100 internal). Analysis from the US health care database resulted in an estimated number of ~75,700 patients, confirming the robustness of the original estimate from the literature. Based on 2 separate analyses, the estimated number of patients with fistulizing CD in the United States is ~77,000 patients.

Sections du résumé

BACKGROUND
Fistulas may arise as a relevant complication of Crohn's disease (CD). Despite their clinical significance and the substantial burden imposed on patients, limited data are available on the epidemiology of fistulizing CD in the United States.
METHODS
A systematic literature review was conducted to identify data published between 1970 and 2017 on the epidemiology of fistulas in patients with CD, with the aim to estimate the number of prevalent cases in the United States. Retrieved titles and abstracts were screened by 2 independent researchers for inclusion criteria (US population-based studies reporting data on the epidemiology of fistulizing CD). To validate the literature-based estimate, data from a US claims database (Truven Health MarketScan database) were analyzed. This database has broad geographic coverage, with health care data for >60 million patients during the period of the analysis.
RESULTS
The literature search retrieved 7 articles for full-text review, and only 1 met the criteria for inclusion. This study described the cumulative incidence of fistulas in a CD population from Minnesota over 20 years. From the reported data, the estimated number of prevalent cases with fistulizing CD in the United States was ~76,600 in 2017 (~52,900 anal, ~7400 rectovaginal, ~2300 enterocutaneous, and ~14,100 internal). Analysis from the US health care database resulted in an estimated number of ~75,700 patients, confirming the robustness of the original estimate from the literature.
CONCLUSIONS
Based on 2 separate analyses, the estimated number of patients with fistulizing CD in the United States is ~77,000 patients.

Identifiants

pubmed: 31216573
pii: 5434953
doi: 10.1093/ibd/izz056
pmc: PMC6799946
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1773-1779

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Références

Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-863
pubmed: 27856364
World J Gastrointest Surg. 2010 Jul 27;2(7):242-6
pubmed: 21160881
Gastroenterology. 2002 Apr;122(4):875-80
pubmed: 11910338
Dig Dis Sci. 2013 Feb;58(2):519-25
pubmed: 22926499
Gut. 1983 Apr;24(4):284-7
pubmed: 6832624
Inflamm Bowel Dis. 2016 Jun;22(6):1456-61
pubmed: 26926039
Dis Colon Rectum. 2011 May;54(5):579-85
pubmed: 21471759
Rev Esp Enferm Dig. 2013 Jan;105(1):3-6
pubmed: 23548004
Mayo Clin Proc. 2012 Dec;87(12):1202-13
pubmed: 23199802
Gut. 1988 Jan;29(1):49-56
pubmed: 3343012
Inflamm Bowel Dis. 2007 Mar;13(3):254-61
pubmed: 17206702
Gut. 2012 Dec;61(12):1686-92
pubmed: 22241842
Inflamm Bowel Dis. 2013 Jun;19(7):1421-7
pubmed: 23518811
Nat Clin Pract Gastroenterol Hepatol. 2009 Feb;6(2):92-106
pubmed: 19153563
Inflamm Bowel Dis. 2014 Nov;20(11):2022-8
pubmed: 25159455
Inflamm Bowel Dis. 2019 May 4;25(6):1054-1060
pubmed: 30346531
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
Aliment Pharmacol Ther. 2003 May 1;17(9):1145-51
pubmed: 12752351
Dis Colon Rectum. 2002 Jun;45(6):771-5
pubmed: 12072629
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027
Am J Gastroenterol. 2008 Aug;103(8):1998-2006
pubmed: 18796097
Gastroenterology. 1998 Jun;114(6):1161-8
pubmed: 9609752
J Crohns Colitis. 2016 Apr;10(4):377-86
pubmed: 26681764
World J Gastroenterol. 2011 Feb 28;17(8):963-7
pubmed: 21448347
Int J Epidemiol. 2012 Dec;41(6):1614-24
pubmed: 23159830
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):487-95
pubmed: 25400993
Dis Colon Rectum. 2012 Jul;55(7):773-7
pubmed: 22706129
Gastroenterology. 2003 Nov;125(5):1508-30
pubmed: 14598268
Tech Coloproctol. 2013 Feb;17(1):89-94
pubmed: 22956209
Inflamm Bowel Dis. 2002 Mar;8(2):106-11
pubmed: 11854609
World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):205-12
pubmed: 25133023
Clin Colon Rectal Surg. 2010 Sep;23(3):169-75
pubmed: 21886466
Colorectal Dis. 2008 Oct;10(8):747-55; discussion 755-6
pubmed: 18462243
Digestion. 2013;88(1):20-5
pubmed: 23797316

Auteurs

David A Schwartz (DA)

Vanderbilt University Medical Center, Nashville, Tennesse, USA.

Ignacio Tagarro (I)

Takeda Spain, Madrid, Spain.

Mary Carmen Díez (M)

TiGenix (Takeda Group), Madrid, Spain.

William J Sandborn (WJ)

The Inflammatory Bowel Disease Center, UC San Diego Health, La Jolla, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH